MET and neoplasm: MET targeting in tumor cells was previously shown to downregulate the TP53-induced glycolysis and apoptosis regulator with successive decrease of intracellular NADPH, leading therefore to a depletion of crucial reducing power, which is essential for the maintenance of cell survival (25).